Skip to main content

Advertisement

SpringerLink
Log in

Drug-eluting coronary stents: as safe as bare-metal stents, but optimized antiplatelet therapy may further improve clinical outcome

  • Editorial Commentary
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Morice M-C, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnar F, Falotico R, the RAVEL Study Group (2002) A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 346:1773–1780

    Article  PubMed  CAS  Google Scholar 

  2. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O’Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE, the SIRIUS Investigators (2003) Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 349:1315–1323

    Article  PubMed  CAS  Google Scholar 

  3. Schofer J, Schluter M, Gershlick AH, Wijns W, Garcia E, Schampaert E, Breithardt G (2003) Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet 362:1093–1099

    Article  PubMed  CAS  Google Scholar 

  4. Schampaert E, Cohen EA, Schluter M, Reeves F, Traboulsi M, Title LM, Kuntz RE, Popma JJ, the C-SIRIUS Investigators (2004) The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol 43:1110–1115

    Article  PubMed  CAS  Google Scholar 

  5. Grube E, Silber S, Hauptmann KE, Mueller R, Buellesfeld L, Gerckens U, Russell ME (2003) TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation 107:38–42

    Article  PubMed  CAS  Google Scholar 

  6. Colombo A, Drzewiecki J, Banning A, Grube E, Hauptmann K, Silber S, Dudek D, Fort S, Schiele F, Zmudka K, Guagliumi G, Russell ME (2003) Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation 108:788–794

    Article  PubMed  CAS  Google Scholar 

  7. Stone GW, Ellis SG, Cox DA, Hermiller J, O’Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, Popma JJ, Russell ME, the TAXUS-IV Investigators (2004) A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 350:221–231

    Article  PubMed  CAS  Google Scholar 

  8. Stone GW, Ellis SG, Cannon L, Mann JT, Greenberg JD, Spriggs D, O’Shaughnessy CD, DeMaio S, Hall P, Popma JJ, Koglin J, Russell ME, the TAXUS-V Investigators (2005) Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. JAMA 294:1215–1223

    Article  PubMed  CAS  Google Scholar 

  9. Dawkins KD, Grube E, Guagliumi G, Banning AP, Zmudka K, Colombo A, Thuesen L, Hauptman K, Marco J, Wijns W, Popma JJ, Koglin J, Russell ME (2005) Clinical efficacy of polymer-based paclitaxel-eluting stents in the treatment of complex, long coronary artery lesions from a multicenter, randomized trial: support for the use of drug-eluting stents in contemporary clinical practice. Circulation 112:3306–3313

    Article  PubMed  CAS  Google Scholar 

  10. Guagliumi G, Farb A, Musumeci G, Valsecchi O, Tespili M, Motta T, Virmani R (2003) Images in cardiovascular medicine. Sirolimus-eluting stent implanted in human coronary artery for 16 months: pathological findings. Circulation 107:1340–1341

    Article  PubMed  Google Scholar 

  11. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, Kutys R, Skorija K, Gold HK, Virmani R (2006) Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 48:193–202

    Article  PubMed  Google Scholar 

  12. Virmani R, Guagliumi G, Farb A, Musumeci G, Grieco N, Motta T, Mihalcsik L, Tespili M, Valsecchi O, Kolodgie FD (2004) Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation 109:701–705

    Article  PubMed  Google Scholar 

  13. Nebeker JR, Virmani R, Bennett CL, Hoffman JM, Samore MH, Alvarez J, Davidson CJ, McKoy JM, Raisch DW, Whisenant BK, Yarnold PR, Belknap SM, West DP, Gage JE, Morse RE, Gligoric G, Davidson L, Feldman MD (2006) Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J Am Coll Cardiol 47:175–181

    Article  PubMed  Google Scholar 

  14. Food and Drug Administration (April 24, 2003) CYPHERä Sirolimus-eluting Coronary Stent on RAPTORÒ Over-the-Wire Delivery System or RAPTORRAILÒ Rapid Exchange Delivery System - P020026: approval order. Rockville, MD: http://www.fda.gov/cdrh/pdf2/P020026.html

  15. Food and Drug Administration (March 4, 2004) TAXUSä Express 2ä Paclitaxel-Eluting Coronary Stent System (Monorail and Over-the-Wire) - P030025. Approval order. Rockville, MD:. http://www.fda.gov/cdrh/pdf3/P030025.html

  16. Farb A, Boam AB (2007) Stent thrombosis redux - the FDA perspective. N Engl J Med 356:984–987

    Article  PubMed  CAS  Google Scholar 

  17. Pfisterer M, Brunner-La Rocca HP, Buser PT, Rickenbacher P, Hunziker P, Mueller C, Jeger R, Bader F, Osswald S, Kaiser C (2006) Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 48:2584–2591

    Article  PubMed  CAS  Google Scholar 

  18. Camenzind E, Steg PG, Wijns W (2007) Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern. Circulation 115:1440–1455 discussion 1455

    Article  PubMed  Google Scholar 

  19. Nordmann AJ, Briel M, Bucher HC (2006) Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta-analysis. Eur Heart J 27:2784–2814

    CAS  Google Scholar 

  20. Food and Drug Administration (2006) Circulatory System Devices Advisory Panel transcript for December 8, 2006 meeting. at http://www.fda.gov/ohrms/dockets/ac/06/transcripts/2006–4253t2.rtf

  21. Mauri L, Hsieh W-h, Massaro JM, Ho KKL, D’Agostino R, Cutlip DE (2007) Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 356:1020–1029

    Article  PubMed  CAS  Google Scholar 

  22. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW (2007) Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 115:2344–2351

    Article  PubMed  Google Scholar 

  23. Spaulding C, Daemen J, Boersma E, Cutlip DE, Serruys PW (2007) A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 356:989–997

    Article  PubMed  CAS  Google Scholar 

  24. Stone GW, Moses JW, Ellis SG, Schofer J, Dawkins KD, Morice M-C, Colombo A, Schampaert E, Grube E, Kirtane AJ, Cutlip DE, Fahy M, Pocock SJ, Mehran R, Leon MB (2007) Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 356:998–1008

    Article  PubMed  CAS  Google Scholar 

  25. Kastrati A, Mehilli J, Pache J, Kaiser C, Valgimigli M, Kelbaek H, Menichelli M, Sabate M, Suttorp MJ, Baumgart D, Seyfarth M, Pfisterer ME, Schömig A (2007) Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 356:1030–1039

    Article  PubMed  CAS  Google Scholar 

  26. Stettler C, Wandel S, Allemann S, Kastrati A, Morice MC, Schömig A, Pfisterer ME, Stone GW, Leon MB, de Lezo JS, Goy JJ, Park SJ, Sabate M, Suttorp MJ, Kelbaek H, Spaulding C, Menichelli M, Vermeersch P, Dirksen MT, Cervinka P, Petronio AS, Nordmann AJ, Diem P, Meier B, Zwahlen M, Reichenbach S, Trelle S, Windecker S, Juni P (2007) Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 370:937–948

    Article  PubMed  CAS  Google Scholar 

  27. Schömig A, Dibra A, Windecker S, Mehilli J, Suarez de Lezo J, Kaiser C, Park SJ, Goy JJ, Lee JH, Di Lorenzo E, Wu J, Juni P, Pfisterer ME, Meier B, Kastrati A (2007) A meta-analysis of 16 randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in patients with coronary artery disease. J Am Coll Cardiol 50:1373–1380

    Article  PubMed  Google Scholar 

  28. Win HK, Caldera AE, Maresh K, Lopez J, Rihal CS, Parikh MA, Granada JF, Marulkar S, Nassif D, Cohen DJ, Kleiman NS (2007) Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. Jama 297:2001–2009

    Article  PubMed  CAS  Google Scholar 

  29. Beohar N, Davidson CJ, Kip KE, Goodreau L, Vlachos HA, Meyers SN, Benzuly KH, Flaherty JD, Ricciardi MJ, Bennett CL, Williams DO (2007) Outcomes and complications associated with off-label and untested use of drug-eluting stents. Jama 297:1992–2000

    Article  PubMed  CAS  Google Scholar 

  30. Kastrati A, Schömig A (2007) Drug-eluting stents: is their future as bright as their past? J Am Coll Cardiol 50:146–148

    Article  PubMed  Google Scholar 

  31. Lagerqvist B, James SK, Stenestrand U, Lindback J, Nilsson T, Wallentin L, the SSG (2007) Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 356:1009–1019

    Article  PubMed  CAS  Google Scholar 

  32. James S. Long term mortality after drug eluting stents in Sweden—one additional year of follow-up. Hotline presentation at ESC Congress 2007; Vienna

  33. Tu JV, Bowen J, Chiu M, Ko DT, Austin PC, He Y, Hopkins R, Tarride JE, Blackhouse G, Lazzam C, Cohen EA, Goeree R (2007) Effectiveness and safety of drug-eluting stents in Ontario. N Engl J Med 357:1393–1402

    Article  PubMed  CAS  Google Scholar 

  34. Shuchman M (2007) Debating the risks of drug-eluting stents. N Engl J Med 356:325–328

    Article  PubMed  CAS  Google Scholar 

  35. Grines CL, Bonow RO, Casey DE Jr., Gardner TJ, Lockhart PB, Moliterno DJ, O’Gara P, Whitlow P (2007) Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation 115:813–818

    Article  PubMed  Google Scholar 

  36. Eisenstein EL, Anstrom KJ, Kong DF, Shaw LK, Tuttle RH, Mark DB, Kramer JM, Harrington RA, Matchar DB, Kandzari DE, Peterson ED, Schulman KA, Califf RM (2007) Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. Jama 297:159–168

    Article  PubMed  CAS  Google Scholar 

  37. Airoldi F, Colombo A, Morici N, Latib A, Cosgrave J, Buellesfeld L, Bonizzoni E, Carlino M, Gerckens U, Godino C, Melzi G, Michev I, Montorfano M, Sangiorgi GM, Qasim A, Chieffo A, Briguori C, Grube E (2007) Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment. Circulation 116:745–754

    Article  PubMed  CAS  Google Scholar 

  38. Gurbel PA, Bliden KP, Samara W, Yoho JA, Hayes K, Fissha MZ, Tantry US (2005) Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study. J Am Coll Cardiol 46:1827–1832

    Article  PubMed  CAS  Google Scholar 

  39. Gurbel PA, Bliden KP, Zaman KA, Yoho JA, Hayes KM, Tantry US (2005) Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study. Circulation 111:1153–1159

    Article  PubMed  CAS  Google Scholar 

  40. O’Donoghue M, Wiviott SD (2006) Clopidogrel response variability and future therapies: clopidogrel: does one size fit all? Circulation 114:e600–606

    Article  PubMed  Google Scholar 

  41. Matetzky S, Shenkman B, Guetta V, Shechter M, Bienart R, Goldenberg I, Novikov I, Pres H, Savion N, Varon D, Hod H (2004) Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 109:3171–3175

    Article  PubMed  CAS  Google Scholar 

  42. Hochholzer W, Trenk D, Bestehorn HP, Fischer B, Valina CM, Ferenc M, Gick M, Caputo A, Büttner HJ, Neumann FJ (2006) Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 48:1742–1750

    Article  PubMed  CAS  Google Scholar 

  43. Buonamici P, Marcucci R, Migliorini A, Gensini GF, Santini A, Paniccia R, Moschi G, Gori AM, Abbate R, Antoniucci D (2007) Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 49:2312–2317

    Article  PubMed  CAS  Google Scholar 

  44. Geisler T, Langer H, Wydymus M, Göhring K, Zurn C, Bigalke B, Stellos K, May AE, Gawaz M (2006) Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J 27:2420–2425

    Article  PubMed  CAS  Google Scholar 

  45. Hochholzer W, Trenk D, Valina CM, Stratz C, Schmiebusch P, Bestehorn HP, Kienzle RP, Büttner HJ, Neumann FJ (2007) Impact of pre-discharge platelet inhibition after loading with clopidogrel on one year clinical outcome of elective coronary stent placement. European Heart Journal 28(Abstract Supplement):509

    Google Scholar 

  46. Price MJ, Endemann S, Valencia R, Gollapudi RR, Levisay JP, Stinis C, Teirstein PS (2007) The response to clopidogrel measured by a point-of-care assay following percutaneous coronary intervention is associated with stent thrombosis over 6-month follow-up. J Am Coll Cardiol 49(Supplement B):906–216 (Abstract)

    Google Scholar 

  47. Angiolillo DJ, Shoemaker SB, Desai B, Yuan H, Charlton RK, Bernardo E, Zenni MM, Guzman LA, Bass TA, Costa MA (2007) Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study. Circulation 115:708–716

    Article  PubMed  CAS  Google Scholar 

  48. Trenk D, Hochholzer W, Müller B, Stratz C, Schmiebusch P, Valina CM, Bestehorn HP, Büttner HJ, Neumann FJ (2007) Adjusted clopidogrel dosing in patients with insufficient platelet inhibition after elective coronary stenting caused a more robust and consistent platelet inhibition in the entire cohort. J Am Coll Cardiol 49:378A(Abstract 1020–1029)

    Article  Google Scholar 

  49. von Beckerath N, Kastrati A, Wieczorek A, Pogatsa-Murray G, Sibbing D, Graf I, Schömig A (2007) A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days. Eur Heart J 28:1814–1819

    Article  Google Scholar 

  50. Wiviott SD, Antman EM, Winters KJ, Weerakkody G, Murphy SA, Behounek BD, Carney RJ, Lazzam C, McKay RG, McCabe CH, Braunwald E (2005) Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Circulation 111:3366–3373

    Article  PubMed  CAS  Google Scholar 

  51. Tantry US, Bliden KP, Gurbel PA (2007) AZD6140. Expert Opin Investig Drugs 16:225–229

    Article  PubMed  CAS  Google Scholar 

  52. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann F-J, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM, for the TRITON-TIMI 38 Investigators (2007) Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357:2001–2015

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Herz-Zentrum Bad Krozingen, Suedring 15, 79189, Bad Krozingen, Germany

    Dietmar Trenk & Franz-Josef Neumann

Authors
  1. Dietmar Trenk
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Franz-Josef Neumann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dietmar Trenk.

Additional information

Both authors have no conflicts of interest to disclose.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Trenk, D., Neumann, FJ. Drug-eluting coronary stents: as safe as bare-metal stents, but optimized antiplatelet therapy may further improve clinical outcome. Eur J Clin Pharmacol 64, 227–232 (2008). https://doi.org/10.1007/s00228-007-0434-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-007-0434-x

Search

Navigation